A study appeared in JAMA on March 4 showing that:
“Among adults with mild COVID-19, a 5-day course of ivermectin, compared with placebo, did not significantly improve the time to resolution of symptoms.”
Ivermectin has been under consideration by the National Institutes of Health (NIH) for treatment of COVID-19. The current NIH recommendation is neither for nor against the use of ivermectin in COVID-19. That recommendation is based on the NIH assessment that there are “insufficient data” to make a recommendation.
In this context, the JAMA article has thus had an immediate impact. As of this writing, the publication has been viewed over 400,000 times. The New York Times broke the news on the same day of the JAMA publication. The headline read:
“Popular Drug Does Not Alleviate Mild Covid-19 Symptoms, Study Finds”
CNN broke the news the following day. The article titled:
“FDA warns against using anti-parasitic drug for COVID-19 after reports of hospitalizations”
CNN did not refer to the JAMA article in its headline but it was one of the topics of the article.
A question has arisen about the study though: “Was it ethical?”
The study, of course...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).